Lv41
700 积分 2022-10-31 加入
678 - Patient-reported outcomes for GSK1070806, an anti-IL-18 monoclonal antibody: a phase 1b, randomised, double-blind, parallel-group placebo-controlled study of patients with atopic dermatitis
7分钟前
已完结
Design and characterization of Zweimab and Doppelmab, high affinity dual antagonistic anti-TSLP/IL13 bispecific antibodies
3个月前
已完结
Development of a novel humanized anti-TSLP monoclonal antibody, QX008N, and exploration of combination therapy of anti-TSLP antibody and anti-IL-4R antibody
3个月前
已完结
Down‐regulation of CD19 expression inhibits proliferation, adhesion, migration and invasion and promotes apoptosis and the efficacy of chemotherapeutic agents and imatinib in SUP‐B15 cells
4个月前
已完结
The Evolving Applications of Bispecific Antibodies: Reaping the Harvest of Early Sowing and Planting New Seeds
7个月前
已完结
Reprogramming macrophage by targeting VEGF and CD40 potentiates OX40 immunotherapy
8个月前
已完结
ICOSL, OX40L, and CD30L Control Persistence of Asthmatic CD4 Trm cells
8个月前
已完结
The role of OX40 ligand/OX40 axis signalling in atopic dermatitis
9个月前
已完结
Select animal models of colitis and their value in predicting clinical efficacy of biological therapies in ulcerative colitis
10个月前
已完结
Risankizumab for Ulcerative Colitis
10个月前
已完结
皖公网安备34019202002308
